Clinical trial · Interventional
Acupuncture for CIPN in Breast Cancer Patients
Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Patients- A Case Series
NCT02615678CI-TRIAL-00038675completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to collect preliminary data on the effectiveness of acupuncture for the treatment of CIPN in breast cancer patients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuropathy | — | UNRESOLVED | — |
| Sensation Disorders | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Acupuncture | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Acupuncture
- description
- Acupuncture including scalp needling will be applied to selected points based on literature
- interventionNames
- Device: Acupuncture
Primary outcomes (1)
- measure
- Changes in perceived neuropathy as measured by EORTC CIPN-20
- timeFrame
- At baseline, week 6 (treatment 12) and at week 10 (treatment 16)
- description
- This is a 20-item self-report multidimensional CIPN specific scale that measures sensory, motor and autonomic symptoms of a 1-4 Likert scale.
Secondary outcomes (3)
- measure
- Changes in perceived neuropathy as measured by Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT-GOG) Questionnaire
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: 1. Minimum of 18 years of age 2. Currently receiving neurotoxic chemotherapy 3. Experiencing symptoms of chemotherapy induced neuropathy for at least 1 month 4. Have a minimum score of 3 on the VAS should have a grade II CIPN on NCICTC 5. Willing to sign an informed consent 6. Stable treatment for more than two months before screening * Stable treatment is defined as no change in the type and dose of medications 2 months prior to enrollment. * Once enrolled, the patients will be asked to remain on the same type and dose of the medications for neuropathy Exclusion Criteria: 1. Receiving any treatment to prevent neuropathy 2 weeks prior to the screening 2. Pre-existing peripheral neuropathy due to any other cause than chemotherapy 3. Pre-existing conditions like pregnancy, uncontrolled diabetes, hypertension, cardiovascular disorders, bleeding disorders, depression (BDI \> 21) 4. Unwilling to follow the protocol 5. Individuals who are receiving government disability assistance
References
Publications (0)
Data not yet available
No reference posted for this study.